Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study.

Respir Res · 2021 · PMC8692825 · PMID 34937570

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach significanceno p-value reported

The EMPACTA trial, recruiting patients with COVID-19 (n = 389) and blood oxygen saturation below 94%, showed reduced likelihood of progression to mechanical ventilation or death, but failed to reach significance on disease survival [ 20 ].

also in 4,113 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.